Enovis (NYSE:ENOV) Trading Down 7.7% – Should You Sell?

Enovis Corporation (NYSE:ENOV)’s stock price traded down 7.7% on Tuesday . The stock traded as low as $23.90 and last traded at $24.2370. 468,952 shares were traded during trading, a decline of 53% from the average session volume of 1,006,268 shares. The stock had previously closed at $26.27.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Needham & Company LLC lifted their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research lifted their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. William Blair started coverage on Enovis in a research note on Friday, April 17th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company upgraded Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $47.43.

Enovis Trading Down 4.0%

The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -1.10 and a beta of 1.47. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The company has a fifty day moving average price of $23.51 and a 200-day moving average price of $26.27.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts predict that Enovis Corporation will post 3.62 EPS for the current year.

Insider Activity

In other news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider directly owned 43,640 shares in the company, valued at $1,112,820. This represents a 2.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders bought 5,000 shares of company stock worth $121,983. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC lifted its holdings in Enovis by 11.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock worth $20,086,000 after purchasing an additional 78,497 shares during the last quarter. Impax Asset Management Group plc lifted its holdings in Enovis by 47.5% in the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Enovis by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Enovis by 56.0% in the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock worth $4,382,000 after purchasing an additional 50,156 shares during the last quarter. Finally, Invenomic Capital Management LP lifted its holdings in Enovis by 22.7% in the 3rd quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock worth $21,622,000 after purchasing an additional 131,705 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.